Tsuyoshi Shirakawa

Office Doctor
Department of Medicine and Biosystemic Science
Kyushu University, Kyushu University Graduate School of Medical Sciences, Fukuoka
Journal Associated: Global Journal of Cancer Therapy Biography:

After I graduated from Kyushu University Graduate School of Medical Sciences in 2004, I started junior residency at Kyushu Medical Center and Kyushu University hospital from 2004 to 2006. Next, I worked as a senior resident at Kyushu Cancer Center hospital in 2006. Then, I researched about cancer stem cells at Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science.

I got Diplomate, Subspeciality Board of Medical Oncology in 2012, and worked as a chief resident National Cancer Center Hospital, Tokyo. At National Cancer Center Hospital, I researched about esophageal cancer chemotherapy mainly.

Then, I joined and worked at the department of Gastrointestinal and Clinical Oncology Division of Kyushu Cancer Center Hospital from 2013 to 2015. From 2015 to 2017, I was a head of Oncology division of Miyazaki Prefectural Miyazaki Hospital, and a main and leading member of Kyushu Medical Oncology Group and Kyushu-Yamaguchi Total Oncology Group, respectively. Now in 2018, I work in Karatsu Higashi-matsuura Medical Association Center as a doctor of internal medicine.

Research Interest:

Medical Oncology (Mainly Gastrointestinal Cancer), Cancer stem cell (Basic research), Palliative medicine, General Medicine, Gastroenterology, Clinical study, Multi-disciplinary coordination and multi-disciplinary study.


Original articles

Acute lymphoblastic leukemia presenting with calcineurin-inhibitor induced pain syndrome after a second allogeneic bone marrow transplantation. Rinsho Ketsueki. 2006 Oct;47(10):1372-6.

A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. Cancer Chemother Pharmacol (2014) 74:1207-15, DOI 10.1007/s00280-014-2597-3.

Improvement in the awareness of palliative care nursing using STAS-J in an acute care hospital. J Palliat Care Med 2015, 5:3 http://dx.doi.org/10.4172/2165-7386.1000219.

Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients. Anti-Cancer Drugs. 2016 Oct; 27(9): 891-8.

Analysis of a questionnaire survey regarding current conditions against exposure to anticancer drugs and reports of cancer chemotherapy at outpatient departments in Japan. Pharmacology & Pharmacy, 2017, 8, 140-152.

Human Nanog pseudogene8 promotes the proliferation of gastrointestinal cancer cells. Exp Cell Res. 2012 Sep 10;318(15):1799-807.

Human STEAP3 maintains tumor growth under hypoferric condition. Exp Cell Res. 2011 Nov 1;317(18):2582-91.

Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases. Anticancer research 2014, 34: 215-220.

Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan. Anticancer research 2014, 34: 2035-2040.

Efficacy and safety analysis of chemotherapy for advanced colitis-associated colorectal cancer in Japan.

Anti-Cancer Drugs 2016, 27(5): 457-63.

Efficacy and Safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer. Anticancer Research 2016 Apr; 36(4): 1959-66.

Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol, 2016 Jul 15 DOI 10.1007/s00280-016-3106-7.

Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G). Gastric Cancer. 2017 May 11 DOI: 10.1007/s10120-017-0725-6.

Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemotherapy Pharmacology, 2017 Jun 26. DOI 10.1007/s00280-017-3371-0.

Irinotecan mnotherapy as third-line or later treatment in advanved gastric cancer. Gastric Cancer, 21(3), 464-472 DOI 10.1007/s10120-017-0759-9.

Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer. Anticancer Drugs, 2017 Sep 12 DOI 10.1097/CAD.0000000000000562.

Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer. Anticancer Res. 2017 Nov;37(11):6459-6468.

Corresponding author

Successful chemoradiotherapy for neuroendocrine tumor grade 3 arising from the mandibular gingiva: a case report and literature review. Open Journal of clinical & medical case report, Volume 2 (2016) Issue 5: 1089.

Case reports

A complete response to second-line chemotherapy with sunitinib of a gastrointestinal stromal tumor: A case report. Molecular and Clinical Oncology 2017 Jul; 7(1): 93-97.

Improvement of quality of life and survival using self-expandable metal stent placement for severe malignant stenosis of the gastric body: a case report. J Med Case Rep. 2012, 6:315.

Systemic chemotherapy for metastatic non-mucinous appendiceal adenocarcinoma: a case report and literature review. Int canc conf J. 2012 Oct DOI10.1007/s13691-012-0060-z.

Successful Chemoradiotherapy for undifferentiated malignant neoplasm arising from the left pulmonary artery Case Rep Oncol 2014;7:484-490.

Successful multimodal therapy for undifferentiated carcinoma with neuroendocrine differentiation in the clival region. Int canc conf J. 2014 July DOI 10.1007/s13961-014-0179-1.

Anti-HER2 combination chemotherapy for advanced gastric cancer associated with the Peutz-Jeghers syndrome: a case report and literature review. Int canc conf J. 2013 Nov DOI 10.1007/s13961-013-0139-1.

Favorable control of advanced colon adenocarcinoma with severe bone marrow metastasis. Molecular and Clinical Oncology 5: 579-582, 2016.